Compare FCUV & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCUV | LYRA |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.6M |
| IPO Year | 2013 | 2020 |
| Metric | FCUV | LYRA |
|---|---|---|
| Price | $4.35 | $1.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 35.2K | ★ 73.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $398,137.00 | ★ $1,534,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.08 |
| 52 Week High | $12.83 | $37.50 |
| Indicator | FCUV | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 38.77 |
| Support Level | $4.81 | $1.21 |
| Resistance Level | $5.25 | $1.52 |
| Average True Range (ATR) | 0.45 | 0.14 |
| MACD | -0.20 | 0.05 |
| Stochastic Oscillator | 36.58 | 64.14 |
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.